Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
Date:11/8/2010

reparing to initiate a Phase IIb study of ANA598, the Company's direct-acting antiviral or DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor StatementStatements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to (i) the plans, timing and trial design of the planned ANA598 Phase IIb and ANA773 Phase IIa studies; (ii) the belief that the design of the planned ANA598 Phase IIb study will support a broad range of potential treatment opportunities in future Phase III studies; (iii) assessments of the potency and safety profile of ANA598 based on the 12 week results; and (iv) references to exploring potential strategic transactions.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies, including the ANA598 data presented at AASLD and available on Anadys' website, may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval.  Also, Anadys cannot provide any assurances that activities related to its exploration of potential strategic transactions will result in a transaction of a particular structure, on favorable terms, or at all. In addition, Anadys' results may be affected by competition from other biotechnology and pharma
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Big Market Research presents a detailed analysis of the ... ( France , Germany , ... Japan . Current scientific views on the Hepatitis ... test volume and sales forecasts by country for HAV NAT, HBV ... HBc Ag, HBe Ag, and ALT/SGPT tests performed in the following ...
(Date:5/5/2015)... YORK , May 5, 2015 ... ("E-QURE" or the "Company"), a premier provider of innovative ... treatment, today issued an update to shareholders and the ... the financing and acquisition of the proprietary Bioelectrical Signal ... the completion of its S-1, as well as its ...
(Date:5/5/2015)... , May 5, 2015  The Association of ... of Recognition™ to The Preoperative Stop and Go ... Ph.D. and Mauricio Gonzalez , M.D., anesthesia providers ... Preoperative Stop and Go Sign product is distributed by ... anesthesia management company, and is in compliance with the ...
Breaking Medicine Technology:2015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 3E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 2E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 3E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 4E-QURE Corp. Issues 2014 - 2015 Update to Shareholders 5The Preoperative Stop and Go Sign Interactive Checklist Awarded AORN Seal of Recognition 2The Preoperative Stop and Go Sign Interactive Checklist Awarded AORN Seal of Recognition 3
... Arlington Medical Resources (AMR), a provider of premier ... finds that more than half of all European inpatients ... Sanofi-Aventis,s Clexane (marketed as Lovenox in the U.S. and ... The European Hospital Anticoagulant Market Guide is a ...
... 28 Tamir Biotechnology, Inc. (Pink Sheets: ... that scientists supported by the National Institute of ... confirming two of our lead compounds outperformed market ... plaque reduction assay (the gold standard) for Cytomegalovirus ...
Cached Medicine Technology:European Hospital Anticoagulant Market Dominated by Sanofi-Aventis's Clexane 2New Discovery Targets Cytomegalovirus (CMV) 2New Discovery Targets Cytomegalovirus (CMV) 3New Discovery Targets Cytomegalovirus (CMV) 4
(Date:5/5/2015)... Skedans Systems a division of ... Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 ... provides tooling to deliver real time information for decision ... Sensor Collaboration Platform is a single unified cloud software ... Web Real Time Communications (WebRTC), and commercial Unmanned Autonomous ...
(Date:5/5/2015)... May 05, 2015 In a April 25, ... The Herald-Times , the Missouri State Highway Patrol (MSHP) announced ... production or use for the second year in a row. ... the FBI, reported 1,469 incidents in 2014 alone, around 15% ... around 2% of the US Population calls Indiana home, according ...
(Date:5/5/2015)... 2015 MAP Health Management, LLC, a ... management for addiction treatment facilities, announced today that Jimmy ... Business Development. Mr. Mooney, who has more than 35 ... be responsible for developing new strategic partnerships with substance ... products and new initiatives. , Prior to joining MAP, ...
(Date:5/5/2015)... York, NY (PRWEB) May 05, 2015 ... Platform that enables businesses to deploy Mobile Engagement Campaigns ... Constant Contact . ProTexting clients can now leverage the ... reach by collecting and syncing subscribers’ e-mail addresses into ... says “We have recognized that the growing trend of ...
(Date:5/5/2015)... 2015 Okyanos, the leader in ... The study was conducted to determine the emotional impact ... and sports-related injuries have had on those affected. ... most prevalent symptom reported at 73%, followed by 66% ... and bending over. Over half of respondents, 56%, said ...
Breaking Medicine News(10 mins):Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2Health News:A Forever Recovery Releases New Information on the Epidemic Rise Of Methamphetamine Abuse in Midwest America 2Health News:Jimmy Mooney, an Addiction Treatment Veteran, Named Vice President of Business Development at MAP Health Management, LLC 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 2Health News:ProTexting SMS Mobile Marketing platform integrates with Constant Contact 3Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 3
... April 20 Waste Management of San Diego was named ... Association on April 18, 2009, at their annual Evening in ... commitment to keeping San Diego,s air clean and ongoing efforts ... join the American Lung Association in working to promote clean ...
... LNCR ), a leading provider of oxygen and ... today announced financial results for the first quarter ended March ... were $371.7 million, compared with net revenues of $415.4 million ... the quarter ended March 31, 2009, was $26.0 million compared ...
... to Release Groundbreaking Study on Economic Impact of Life Sciences ... State SEATTLE, April 20 An alliance of ... "We Work for Health," a landmark statewide effort to enhance ... sciences industry and to promote the growth and success of ...
... and genetics are among research targets , , MONDAY, April ... that influence cancer risk are finding important new clues ... us believe that prevention is better than trying to ... Dr. Peter Shields, deputy director of the Lombardi Comprehensive ...
... led to poorer outcomes, study finds , , MONDAY, April ... been exposed to radiation have more aggressive disease and ... , Researchers at Mount Sinai Hospital in Toronto studied ... -- for example, in the workplace, through environmental exposure, ...
... the University of Chicago Medical Center have found that ... rapamycin can increase drug levels, allowing lower doses of ... the combination can be effective in treating various types ... pasted DO-NOT-TAKE-WITH-GRAPEFRUIT-JUICE stickers on various pill bottles because it ...
Cached Medicine News:Health News:Waste Management Honored by American Lung Association for Environmental Achievements 2Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 2Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 3Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 4Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 5Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 6Health News:Lincare Holdings Inc. Announces First Quarter 2009 Financial Results 7Health News:Life Sciences Leaders to Launch Statewide 'We Work for Health' Economic Development and Jobs Campaign 2Health News:Experts Highlight Inroads to Preventing Cancer 2Health News:Experts Highlight Inroads to Preventing Cancer 3Health News:Radiation Exposure Linked to Aggressive Thyroid Cancers 2Health News:Grapefruit juice boosts drug's anti-cancer effects 2Health News:Grapefruit juice boosts drug's anti-cancer effects 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: